|
|
Friday, September 15, 2017
|
|
|
Here's the latest news in health and medicine. For more, check out
statnews.com and follow us on
Facebook and
Twitter.
|
By
Meghana Keshavan
|
|
Amanda Lucier for STAT
PORTLAND, Ore. — Dr. Vinay Prasad is a professional scold: He takes to Twitter each day to critique this cancer drug as ineffective, or blast that one as overpriced, or dismiss the clinical trial of another
as completely irrelevant.
So it’s a bit of a surprise to catch him at the bedside of an elderly man with lymphoma, laughing gently with his patient as he inquires about his day — and painstakingly explains a potent drug’s unpleasant
side effects.
Read
More
|
By
Leah Samuel
|
|
NBC/Newsmakers via Getty Images
Medical storylines have riveted television viewers since the earliest days of the medium — and for just as long, TV writers and directors have had to navigate the age-old tension between truth and storytelling.
One early solution, beginning in the 1950s, was a group of doctors who advised television producers directly. The group, known as the Physician’s Advisory Committee (PAC) on Television, Radio, and Motion
Pictures, reviewed scripts, helped find props, and showed actors how to properly hold a scalpel.
Read
More
|
By
Megan Thielking
|
|
Michelle McGaughey for STAT
It’s been a busy week in the world of health and medicine, from two new health care reform plans to new cancer screening guidelines.
We get you ahead of the day’s health news every weekday with our
Morning Rounds newsletter. How well did you keep up? Take our quiz and find out.
Read
More
|
Sponsor content by STAT News
Join our free chat: Why are there no good Alzheimer’s drugs?
Drug companies have spent billions of dollars on it. Academics have devoted decades to it. So where are the new drugs for Alzheimer’s disease? Join STAT reporters Sharon Begley and Damian Garde on September
18 for a free live chat with Dr. Reisa Sperling of Brigham and Women’s Hospital — one of the world’s leading experts on Alzheimer’s disease — for an interactive discussion on the past, present, and future of treating Alzheimer’s.
Register now.
|
|
|
|
By
Stephanie L. White
|
|
AP
As an African-American physician who has experienced the effects of racism, I should be comfortable talking about it. I’m not — but I need to be.
That feeling was reinforced by a
horrifying news story from the New Hampshire community where I work as a pediatrician. The mother of an 8-year-old biracial boy said he had nearly been lynched by some white teenagers. The image his mother posted on social
media before driving him to the hospital where I work showed rope burns on his neck consistent with being hung.
Read
More
|
By
Adam Feuerstein
|
|
Keith Bedford/The Boston Globe
A $7 billion market valuation and the credibility of the entire field of RNA interference drug development is riding on the results of
Alnylam Pharmaceuticals’ (ALNY)
next big clinical trial.
No pressure, folks.
Read
More
|
|
|
|
|